Antibacterial properties of Ro 13-99041, a long-acting new cephalosporin.
The antibacterial properties of the new cephalosporin RO 13-9904 were investigated in vitro and in vivo. The compound showed good activity against Entero-bacteriaceae and gram-positive cocci, except Streptococcus faecalis. Haemophilus influenzae, Neisseria gonorrhoeae and Neisseria meningitidis were extremely susceptible to Ro 13-9904. The bactericidal activity of Ro 13-9004 was comparable to that of cefotaxime. The new cephalosporin showed better therapeutic efficacy in mice against Pseudomonas aeruginosa than cefotaxime, cefoperazone, azlocillin, and piperacillin. Ro 13-9904 was highly effective in prophylactic studies, in contrast to cefotaxime, SCE-1365, cefoperazone and piperacillin. This indicates that Ro 13-9004 essentially differs from other beta-lactam compounds in showing unusually prolonged in vivo efficacy.
D000818:Animals; D001419:Bacteria / Q000187:drug effects*; D002443:Ceftriaxone; D002511:Cephalosporins / Q000378:metabolism / Q000494:pharmacology*; D004755:Enterobacteriaceae / Q000187:drug effects; D006190:Haemophilus / Q000187:drug effects; D006207:Half-Life; D066298:In Vitro Techniques; D051379:Mice; D008826:Microbial Sensitivity Tests; D009343:Neisseria / Q000187:drug effects; D011549:Pseudomonas / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects
D002511:Cephalosporins; D002443:Ceftriaxone